Top line stable.
+6.0% YoY versus +4.3% prior. 3y CAGR +5.6%.
+6.0%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $579.8B
Live price unavailable
Fundamentals as of 2026-03-29
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
2 of 3 legendary models say HOLD JNJ — but Warren Buffett disagrees.
What would legendary investors pay for JNJ?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Yes — Johnson & Johnson's 25.9% ROE ranks above the S&P 500 median, and D/E 1.47 stays within healthy bounds.
Financial story
Yes — Johnson & Johnson's 25.9% ROE shows strong capital efficiency, and its 1.47 debt-to-equity stays within healthy bounds.
Bottom line: JNJ is rated BUY by 2 of 3 legendary models, with 0 holding and 1 flagging it overvalued, but earns a C sector grade (57/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
Buffett, Lynch, and Munger evaluate JNJ against their respective frameworks. Per-model fair value and reasoning are in the valuation tab.
JNJ's P/E ratio is 26.3x. 5-year P/E history is in the financials tab.
1 of 3 legendary models say BUY. Full breakdown by investor and signal is in the valuation tab.
JNJ's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
JNJ is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
1 of 3 legendary investor models rate JNJ a BUY. Fair value estimates and full investor breakdown are in the valuation tab
P/E 26.9x — 18% above the 5y median of 22.9x. Forward 20.1x hints at EPS expansion next year.
Strength. Revenue grew +9.9% to a record $24.1B *through* the Stelara cliff — the pipeline absorbed a 60% collapse in a former blockbuster.
Risk. The defense is priced in: at ~20x forward earnings, a premium to peers, the market already assumes the new drugs keep winning the race.
How does JNJ compare?
See exactly where JNJ ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingJNJ sits at #25 in Healthcare with a C grade (57/100).